Fig. 5. Screen of FDA-approved anti-cancer drugs combined with BH3-mimetics.
CHLA-20 cells were exposed to at 0.03, 0.3, 3, or 30 μM of the anti-cancer approved drug library containing 397 compounds either alone (control) or in combination with the MCL1 inhibitor S63845 (1 μM) or the BCL2/BCL-XL inhibitor ABT263 (0.1 μM). Cell viability was assessed at 72 h using CTG assay. The mean effect of 3–5 experiments was calculated and drug efficacy was displayed as colour coding with red showing highest effects. Compounds were sorted by calculating the combined additional effect of ABT-263 across all concentrations, and the 100 most effective compounds are shown.